The treatment landscape of advanced renal cell carcinoma (RCC) continues to shift as both new targeted therapies and immunotherapies show efficacy in treating the disease. Contemporary insights into the molecular characterization of RCC are likely to fuel the development of additional therapies. This review summarizes recent advancements in the biologic characterization of RCC and discusses newly approved therapies and ongoing studies in the treatment of advanced RCC.
INTRODUCTION
Renal cell carcinoma (RCC) is the eighth most common malignancy in the United States, with an estimated 62 700 new cases and 14 240 estimated deaths in 2016 [1] . At presentation, one-third of patients have metastatic disease, and upwards of 30% of patients with localized disease will develop distant metastases after nephrectomy [2, 3] . The high burden of advanced disease highlights the need for systemic therapies. In this review, we highlight new insights into the biology of RCC along with recent advances in targeted therapy and immunotherapy.
MOLECULAR CHARACTERIZATION OF RENAL CELL CARCINOMA
RCC is an umbrella term for several cancers arising in the kidney that are genetically and morphologically distinct [4] . Currently, the WHO recognizes 16 subtypes of RCC [5] , and up to 12 hereditary conditions have been identified with increased lifetime risk of developing renal tumors [6] . The biology of the three most common histologic subtypes has recently been profiled by The Cancer Genome Atlas: clear cell [7 && ], papillary [8 && ], and chromophobe RCC [9 && ]. Clear cell RCC (ccRCC) is the most common histologic subtype, accounting for approximately 75% of cases. Inactivation of von Hippel-Lindau (VHL) either by mutation or epigenetic silencing occurs in over 90% cases of sporadic ccRCC. Additionally, The Cancer Genome Atlas (TCGA) analysis has demonstrated recurrent mutations in several chromatin remodeling genes, including PBRM1 (32.9%), SETD2 (11.5%), and BAP1 1 and type 2 pRCC, and found four distinct molecular subgroups with progressively worse survival (C1, C2a, C2b, and C2c). C1 consisted of mostly type 1 pRCC tumors, characterized by gain of chromosome 7 and 17, as well as alterations in MET. In contrast to the hereditary form of pRCC, hereditary papillary renal cancer which is characterized by germline MET mutations [10] , somatic alterations of MET in nonhereditary pRCC was less common, occurring in $15% of cases.
Type 2 pRCC could be further classified into subgroups C2a, C2b, and C2c. C2a consisted of early stage tumors, whereas C2b consisted of later stage tumors and was characterized by mutations in SETD2. C2c had the poorest survival and was associated with a CpG island methylator phenotype. Other alterations in type 2 pRCC included loss of cyclin dependent kinase inhibitor 2a, activation of the nuclear factor erythroid 2 oxidative stress pathway, mutations of FH which encodes fumarate hydratase gene fusions involving the MiTF gene family members TFE3 and TFEB, and mutations in chromatin remodeling genes.
Chromophobe RCC (chRCC) accounts for around 5% of RCC cases. In comparison with ccRCC and pRCC, it usually exhibits relatively indolent behavior with 90% 10-year survival [11] ; however, locally invasive and metastatic disease can occur [12] . The analysis from TCGA demonstrated that chRCC exhibit alterations in mitochondrial DNA and that 10% of cases had rearrangement in the TERT promoter. The majority of cases (86%) exhibited loss of most or all of chromosomes 1, 2, 6, 10, 13, and 17. Furthermore, TP53 was mutated in 32% of cases, and mammalian target of rapamycin (mTOR) pathway changes occurred in 23% of cases.
Together, the three TCGA reports highlight the genetic diversity of RCC. A better understanding of the molecular pathways driving these diseases may lead to the development of additional targeted therapies.
THE STATE OF TREATMENT FOR CLEAR CELL RENAL CELL CARCINOMA

Targeted therapy
Understanding the biologic basis of ccRCC has led to the development of multiple therapies targeted against downstream consequences of VHL inactivation. In total, there are 11 FDA-approved agents for RCC, with three main therapeutic approaches: vascular endothelial growth factor (VEGF) pathway inhibition, mTOR pathway inhibition, and immunotherapy (Table 1) . Prior to 2016, there were five approved therapies targeting downstream mediators of the hypoxia inducible factor (HIF) activation pathway (sunitinib [15] , sorafenib [14] , bevacizumab [18, 26] , pazopanib [20] , and axitinib [21] ), two drugs that target the mTOR pathway (temsirolimus [16] and everolimus [17] ), and a cytokinebased immunotherapy (interleukin-2 [13] ). Over the last 18 months, three new agents have been approved: cabozantinib, lenvatinib, and nivolumab.
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) that targets the VEGF, MET, and AXL pathways. Both the MET and AXL pathways are implicated in the development and metastasis of ccRCC through the VHL-HIF axis [27] . AXL is activated by HIF-1 and HIF-2, and inactivation of AXL decreases lung metastases in mice xenograft models of RCC. A phase III randomized study compared cabozantinib and everolimus in 658 patients with metastatic renal cell carcinoma (mRCC) who had progressed after VEGF-targeted therapy [23 && ]. Patients were randomly assigned (1 : 1) to receive cabozantinib (60 mg daily) or everolimus (10 mg daily); the primary end point of the study was progression-free survival (PFS), whereas overall survival (OS) and objective response rate (ORR) were secondary end points. Based on the primary end point analysis, the
KEY POINTS
Our understanding of the biology of RCC has been greatly improved with the recent molecular characterization of three kidney cancer subtypes: ccRCC, pRCC, and chRCC.
The therapeutic landscape for advanced RCC continues to evolve with the addition of three new agents approved for use in the second line.
The approval of nivolumab, an immune checkpoint inhibitor, marks the availability of a new class of therapies and will provide the basis of evaluation of novel combination strategies.
The role of adjuvant therapy for nonmetastatic RCC remains unclear with conflicting data emerging from recent studies. study concluded that cabozantinib was superior to everolimus in this setting (median PFS 7.4 versus 3.8 months; hazard ratio (HR) 0.51; P < 0.0001). Additionally, both the ORR (17 versus 3%, P < 0.0001) and OS (21.4 versus 16.5 months, HR 0.66, P ¼ 0.00026) were superior in patients receiving cabozantinib. Both agents were well tolerated, with adverse events managed by dose reduction (60% for cabozantinib and 25% for everolimus). On the basis of these data, cabozantinib was approved as a second-line agent in April 2016.
Following publication of these data, the efficacy of cabozantinib in the front-line setting is being explored ( Other approaches to target more proximal consequences of VHL inactivation in ccRCC are the subject of active preclinical evaluation. Two recent studies have evaluated direct inhibition of HIF-2a with a small molecular inhibitor, PT2300 in ccRCC models. Cho and colleagues [31 & ] showed that PT2300 inhibits growth of VHL-deficient ccRCC cell lines in vitro and in mouse xenografts. In a separate study, Chen and colleagues [32 & ] assessed the efficacy of PT2300 in a patient-derived mouse xenograft model, demonstrating decreased cell growth in 10 out of18 (56%) animals treated.Taken together, these studies demonstrated the ability to induce antitumor effects by directly targeting HIF-2a. This approach is currently being evaluated in patients with the oral HIF-2a inhibitor, PT2385 (NCT02293980). Further exploration of this strategy in clinical trials will define the role of this class of therapy for patients with VHL-deficient RCC. 
Immunotherapy
Owing to a lack of durable complete responses to targeted therapies, there has been a resurgence of interest in immunotherapy to treat RCC. Historically, the role of immune modulation in RCC was suggested by observations that metastatic lesions could spontaneously regress after radical nephrectomy to remove the primary tumor [33] . Together with evidence that tumor-infiltrating lymphocytes [34, 35] , circulating cytokines [36] , and chemokines [37] are elevated in patients with RCC, there seems to be a complex interaction between tumor and host immune response in patients with RCC. Early phase results of several emerging immunotherapies have been reviewed recently [38] . This review will focus on the evidence for checkpoint blockade. Programed death 1 (PD-1) is a cell surface protein in the B7-CD28 family. PD-1 is expressed on T cells and a ligand, Programmed death-ligand 1 (PD-L1), is expressed both on tumor cells and tumorinfiltrating lymphocytes and myeloid lineage cells. PD-1 is a negative regulator of T-cell activation, and engagement by its ligand(s) results in inhibition of cytokine production, proliferation, and cytotoxic activity of T cells [39] . Expression of PD-L1 on tumor cells might allow tumors to escape immune surveillance and is associated with poorer survival in at least one study [40] . Many tumors, including RCC, can upregulate these cell surface immune checkpoint proteins that block T-cell function in response to inflammation in a process known as adaptive immune resistance [41] . A phase III trial in the second and third-line setting showed that PD-1 blockade using the monoclonal antibody nivolumab resulted in improved OS as compared with everolimus [22 && ]. A total of 821 patients with advanced RCC with a clear cell component who had progressed on treatment with one or two antiangiogenic agents were randomized to receive either 3 mg/kg of nivolumab every 2 weeks or 10 mg of everolimus daily. OS was the primary end point but ORR and safety were also assessed. The most common prior therapy was sunitinib (59%), followed by pazopanib (30%). Most patients were intermediate risk (49%), and the majority of patients had a prior nephrectomy (88%). The median OS was 25 months (95%CI 21.8-not estimable) for nivolumab and 19.6 months (95% CI 17.6-23.1) for everolimus (HR 0.73; 98.5% CI 0.57-0.93; P ¼ 0.002). This improvement in OS met the prespecified threshold for superiority outlined in the trial design (P 0.0148). Nivolumab was also associated with a better ORR than everolimus (25 versus. 5%; odds ratio 5.98, P < 0.001), but did not lead to an improved PFS; median PFS was 4.6 months (95% CI 3.7-5.4) for nivolumab and 4.4 months (95% CI 3.7-5.5) with everolimus (HR 0.88; 95% CI 0.75-1.03; P ¼ 0.11). The FDA approved nivolumab for use in the second-line setting in 2015.
There is significant interest in combining PD1/ PDL-1 inhibitors with other agents, including other checkpoint inhibitors, VEGF inhibitors, Histone deacetylase inhibitors, and vaccines (Table 3) .
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is another checkpoint inhibitor that is expressed on suppressive, regulatory T cells and activated T cells. Ipilimumab, a CTLA-4 inhibitor, is FDA approved in melanoma, and the combination of PD-1/CTLA-4 blockade appears to be synergistic in the treatment of metastatic melanoma [42] . Phase I data on the combination of ipilimumab and nivolumab in patients with mRCC were recently presented by Hammers et al. [43] . Objective responses were seen in up to 43% of patients, with a median duration of response of 53.9 weeks. However, treatment-related adverse events occurred in 88% of patients, with grade 3-4 adverse events in 34-64% of patients. Based on the preliminary efficacy of this approach, the combination of PD-1 blockade and CTLA-4 blockade is currently being evaluated in the first-line setting in RCC. Checkmate 214 (NCT02231749) is a phase III trial comparing nivolumab combined with ipilimumab versus sunitinib in previously untreated patients with metastatic ccRCC; the trial has completed accrual and results are awaited [44] .
Given that the majority of FDA-approved therapies for RCC are VEGF inhibitors, the utility of combining these agents with immune checkpoint blockade is under investigation. Indeed, VEGF pathway inhibitors seem to have an immunomodulatory effect. Sunitinib has been associated with decreasing regulatory T-cell numbers, thereby enhancing an antitumor immune response [45] . Furthermore, both sunitinib and sorafenib downregulate the function of suppressive tumor-associated macrophages [46, 47] . Preliminary data from a phase I trial of nivolumab (2 mg/kg intravenous) and sunitinib CTLA-4, cytotoxic T-lymphocyte-associated protein 4; mRCC, metastatic renal cell carcinoma; PD-1, programed death 1; RCC, renal cell carcinoma. Modified from permission [38] .
(50 mg, 4 weeks on, 2 weeks off) or pazopanib (800 mg daily) in previously treated metastatic RCC demonstrated notable antitumor activity with an ORR of 52% in the sunitinib arm and 45% in the pazopanib arm [48] ; however, the combination was also associated with increased toxicity, with grade 3-4 adverse events occurring in 73% and 60% of patients in the sunitinib and pazopanib arms, respectively, and with heightened concern for hepatotoxicity with the latter regimen. Ongoing studies attempt to mitigate the potential risk of combination therapy by utilizing newer, more specific VEGF pathway antagonists. Preliminary results from a phase 1 study of axitinib and pembrolizumab in treatment-naive mRCC demonstrated a 67.3% ORR, with two complete responses [49] . Grade 3-4 adverse events occurred in 52% of patients. Additional studies, including axitinib in combination with avelumab in the first-line setting (NCT02493751) and pembrolizumab and axitinib in the second-line setting (NCT02133742) are ongoing (Table 3) . Additionally, the combination of an anti-VEGF antibody with immunotherapy has shown efficacy in a preclinical study [50] which may be mediated by the ability of anti-VEGF antibodies to normalize the tumor vasculature and permit emigration of activated antitumor T cells. A phase Ib study of atezolizumab, an anti-PD-L1 antibody, combined with bevacizumab demonstrated an ORR of 40% with no grade 3-4 adverse events [51] . Similarly, Dudek et al. designed a phase Ib/II trial of bevacizumab and pembrolizumab in patients with metastatic ccRCC. The phase Ib portion of the trial recently reported that the combination was well tolerated with no dose-limiting toxicity or serious adverse events and no grade 3 or 4 drug-related toxicities. This established a 200 mg fixed dose of pembrolizumab and 15 mg/kg dose of bevacizumab, both given every 3 weeks, as the regimen to be evaluated in the ongoing phase II portion of the study (NCT02348008) [52] . Although preliminary, these data suggest that the combination of anti-VEGF antibodies with PD-1 blockade may be more tolerable than VEGF TKI/ checkpoint blockade combination therapies. A phase II study of atezolizumab in combination with bevacizumab or sunitinib in the first-line setting is also currently underway (NCT01984242; Table 3 ).
With so many therapies now available, there is a plethora of agents to choose from in both the front line and subsequent lines of therapy. However, there is a dearth of evidence for the optimum initial selection and subsequent sequencing of agents [25, 53] . Based on current data, VEGF pathway antagonists remain the best choice for front-line therapy in most patients with advanced ccRCC, although high-dose interleukin-2 is a reasonable consideration in selected patients. However, newer agents, including cabozantinib and nivolumab, have supplanted single agent everolimus as optimal initial choices for patients who have progressed on VEGF pathway antagonists. Ongoing combination studies, as well as novel targeted approaches, are likely to further alter the optimal treatment choices and maximize oncologic outcomes.
THE STATE OF TREATMENT FOR NONCLEAR CELL RENAL CELL CARCINOMA
Although there are no FDA-approved therapies for non-ccRCC, emerging data are beginning to shed some light on the utility of current therapies for patients with non-ccRCC (Table 4) . Within this arena, most of the data is for pRCC [54] . The Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer (SUPAP) trial was a phase II study that evaluated the efficacy of sunitinib for locally advanced or metastatic pRCC [55] . Efficacy was demonstrated for both type 1 pRCC (median PFS 6.6 months, OS 17.8 months) and type II pRCC (median PFS 5.5 months, OS 12.4 months). The RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe (RAPTOR) study evaluated the efficacy of everolimus in pRCC in 92 patients, and demonstrated efficacy in both type 1 pRCC (OS 28 months) and type 2 (OS 20 months) pRCC. Two comparative phase II trials recently evaluated VEGF inhibition versus mTOR blockade in patients with metastatic non-ccRCC. The Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma trial (ESPN Trial) compared sunitinib versus everolimus in the first-line setting [56] . The patient population included all subtypes of non-ccRCC as well as ccRCC patients with at least 20% sarcomatoid component, with a primary end point of PFS in the first-line setting in an effort to demonstrate superiority of everolimus. There was no statistical difference between the treatments, and the trial was stopped and accrual halted at the time of interim analysis. A second randomized phase II study, Phase II Study of Afinitor Vs. Sutent in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN), in 108 patients with treatment-naive metastatic pRCC, chRCC, or unclassified non-ccRCC subtypes [57] demonstrated that Sunitnib was associated with an improved PFS (8.3 versus 5.6 months; HR 1.4; P ¼ 0.16) compared with everolimus.
Though there is a lack of trial data to support the use of checkpoint inhibitors in non-ccRCC, there is some biologic rationale for their use. Many nonccRCC express PD-L1, including 5.6% of chRCC, 10% of pRCC, 30% of Xp11.2 translocation RCC, and 20% of collecting duct carcinomas [58] . Trials of checkpoint inhibitors in non-ccRCC are needed to test whether this biologic rationale translates to clinical efficacy.
Other ongoing trials in pRCC include phase II studies of selective Met inhibitors, including INC280 and AZD6094, and the combination of the epidermal growth factor receptor (EGFR) inhibitor erlotinib with bevacizumab [59] , as summarized in Table 4 .
ADJUVANT/NEOADJUVANT THERAPY
With the advent of agents active in metastatic disease, there is growing enthusiasm for utilizing systemic therapy in the adjuvant or neoadjuvant setting in an attempt to alter the natural history of advanced RCC. Several large adjuvant studies of VEGF and mTOR pathway-directed agents were undertaken soon after the approval of these agents in the metastatic setting; results from the earliest of these studies are now becoming available. Data from one such study, the Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma (ASSURE trial), were reported recently [15] . This phase III trial of 1943 patients with high-grade T1b or higher nonmetastatic RCC randomized to receive 54 weeks of sunitinib, sorafenib, or placebo demonstrated no improvement in outcome with adjuvant VEGFR TKIs (median PFS 5.8 years; HR 1.02; P ¼ 0.8 for sunitinib versus 6.1 years; HR 0.97; P ¼ 0.7 for sorafenib versus 6.6 years for placebo). There was a high rate of treatment-related discontinuation (44 and 45%) in the sunitinib and sorafenib arms, potentially attenuating any biologic effect in the intention to treat analysis.
In contrast, results from Sunitinib as Adjuvant treatment for patients at high risk of recurrence of renal cell carcinoma following nephrectomy (S-TRAC), a phase III trial that randomized 615 patients with T3 or greater RCC to sunitinib versus placebo for 1 year [30] suggest that sunitinib was associated with improved disease-free survival compared with placebo (6.8 versus 5.8 years, P ¼ 0.03). Treatmentrelated discontinuation on this study was lower than that seen in the ASSURE trial (28.1%). These conflicting data may be a reflection of the fact that S-TRAC enrolled patients with more advanced disease and was restricted to ccRCC, compared with ASSURE. At the present time, the role of adjuvant treatment after nephrectomy remains unclear and further evaluation is necessary to clarify the clinical benefits of this strategy. Several ongoing trials (Table  2) are evaluating axitinib, everolimus, and sorafenib versus placebo in the adjuvant setting. Trials using PD-1 inhibitors in the adjuvant space are now underway as well (Table 2 ).
In the neoadjuvant setting, existing trials have focused mainly on downsizing locally advanced tumors. Karam and colleagues [60] demonstrated that the median reduction of primary renal tumor diameter was 28.3% in patients treated with neoadjuvant axitinib in a phase II study. In a follow-up study, the feasibility of partial nephrectomy before and after neoadjuvant axitinib was assessed by querying urologists blinded to treatment status [61] . The feasibility of partial nephrectomy increased 22.8-fold after treatment with axitinib. Similarly, the use of neoadjuvant-targeted therapy prior to inferior vena cava thrombectomy results in tumor shrinkage in 44% of patients, but only one of 25 patients had a change in surgical approach secondary to tumor shrinkage [62] . Ongoing neoadjuvant studies are evaluating the role of everolimus, Treatment of advanced renal cell carcinoma Ball et al.
sunitinib, pazopanib, and nivolumab as summarized in Table 2 . The role of neoadjuvant therapy is currently unclear in the majority of patients and this approach is largely restricted to the clinical trial setting. Several trials are evaluating the combination of systemic therapy and surgery for metastatic disease. A recent study evaluated the role of preoperative pazopanib before cytoreductive nephrectomy in patients with metastatic RCC [63] . In 104 patients who received pazopanib, 61% went on to undergo nephrectomy. Median PFS was 7.1 months, and OS 22.7 months. Biomarker analysis demonstrated a decrease in cluster of differentiation 8 lymphocytes, reduction in expression of VHL and C-Met, and increase expression of PD-L1; however, no biomarkers correlated with treatment. Finally, Eastern Cooperative Oncology Group 2810 is a phase III trial currently open to accrual, comparing adjuvant pazopanib versus placebo after metastasectomy (NCT01575548). Although aggressive surgical intervention can often provide considerable benefit to patients with advanced RCC, careful patient selection and treatment by experienced surgical teams at high-volume centers should be considered.
CONCLUSION
Advances in targeted therapy and immunotherapy have led to approval of three new drugs for advanced RCC over the last 18 months. Although VEGFR inhibitors remain the standard first-line treatment for the majority of patients, this paradigm is being challenged by ongoing studies. In the post-VEGFR therapy setting, everolimus has been supplanted by other therapies, including cabozantinib and nivolumab, but may still have a role in subsequent lines of therapy. The current landscape is notable for a dearth of therapies for non-ccRCC and for evidence regarding the optimal sequencing of agents for patients with progressive disease. The search for actionable diagnostic, therapeutic, and prognostic RCC biomarkers continues. Additional work is also needed to understand the role of neoadjuvant/adjuvant systemic therapy and combination therapies, and the impact such strategies will have on survival and quality of life measures.
